Pediatrics Doctors in Rowlett, TX Accepting Medicare

5 Pediatrics doctors found. Showing 1 - 5

Dr. Vincent Robert Iannelli, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9100 Lakeview Pkwy, Rowlett, TX 75088 Phone: 972-412-3034    Fax: 972-412-1949

Dr. Pamela M. M. Wieland, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6900 Scenic Dr, Ste 103, Rowlett, TX 75088 Phone: 972-412-1034    Fax: 972-475-5708

Dr. Kristen Deann Waw, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9100 Lakeview Pkwy, Rowlett, TX 75088 Phone: 903-818-3690

Dr. Susan Michaelle Smart, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9100 Lakeview Pkwy, Rowlett, TX 75088 Phone: 972-412-3034    Fax: 972-412-1949

Dr. Dynal M. London, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6900 Scenic Dr, Ste 103, Rowlett, TX 75088 Phone: 972-412-1034    Fax: 972-475-5708

News Archive

FDA announces availability of investigational test to screen donated blood for Zika virus

The U.S. Food and Drug Administration today announced the availability of an investigational test to screen blood donations for Zika virus. The screening test may be used under an investigational new drug application (IND) for screening donated blood in areas with active mosquito-borne transmission of Zika virus.

UAB dietitian suggests five foods for healthier eating

With the hectic hustle and bustle of daily life — managing family, career, home and more — it is no wonder that creativity in the kitchen can fall to the wayside. To help people get out of a food rut and eat healthier this year, a dietitian from the University of Alabama at Birmingham (UAB) suggests adding five foods to the grocery cart.

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.

New hope for schizophrenia sufferers

Key research from the University of New South Wales (UNSW) could lead to the first early diagnostic tool for schizophrenia and bipolar disorder.

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

Read more Medical News

› Verified 8 days ago